DraganFly ($DFLY) and Windfall Geotek ($WIN) have combined world-class drone technology with artificial intelligence to create an “incomparable solution” solving the global landmine epidemic.
With 60 – 110 million landmines needed to be found, the market is estimated to be worth $700M per year … But that pales in comparison to the value of lives that will be saved and economic prosperity created from ridding regions plagued by landmines.
Vaughan, Ontario–(February 16, 2021) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce that its wholly-owned subsidiary, Spyder Cannabis Subco Inc. (“Spyder Subco“), has received notice from the City of Pickering regarding an initial inspection of the Company’s proposed cannabis dispensary located at 776 Liverpool Rd., Unit 4, Pickering, Ontario, L1W 1S2. Spyder Subco has a Retail Operator License issued by the Alcohol and Gaming Commission of Ontario (the “AGCO“) and currently operates a cannabis dispensary in Niagara Falls, Ontario.
In anticipation of the city’s approval of the sale of cannabis in Pickering, the Company secured a retail premises and began to build out the location in 2019. The inspection is scheduled to take place during the week of February 16, 2021. Subject to passing the inspection, and making any necessary modifications, Spyder Subco will be placed in the queue of applications and will await receipt of a Retail Store Authorization from the AGCO for the new premises, permitting the Company to begin operating a licensed cannabis dispensary in Pickering and its second dispensary in Ontario.
Dan Pelchovitz, President & CEO of Spyder, commented, “Pickering is strategically located where Toronto, York and Durham Regions meet, and boasts a growing population of approximately 100,000 residents. Spyder’s team is excited to bring its brand name and best-in-class customer service to one of the fastest growing cities in Ontario.”
Read More: https://agoracom.com/ir/SpyderCannabis/forums/discussion/topics/755397-spyder-cannabis-provides-update-on-cannabis-dispensary-application-in-pickering/messages/2303797#message
Our thesis at AGORACOM is that small cap disruptive technology companies are going to create 3X more wealth this decade than the last 3 decades combined, thanks to the convergence of powerful tech such as Artificial Intelligence, IoT sensors and so on.
Why? The costs to develop, deploy and scale new applications powered by these new technologies have come down to a point where small cap companies can compete head to head with just about anybody. In fact, their size makes them more nimble and able to pivot into emerging trends much quicker than most tech giants.
Which companies will actually succeed in delivering is a determination you have to make. But one company to consider is Predictiv AI (PAI:TSXV / INOTF:OTCQB), whose proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector.
In layman’s terms, PAI uses AI and Machine learning to create solutions that can predict danger.
For example, the Company’s Thermal Pass Fever Detection System was recently used at a Carolina Panthers NFL game. Watch this short video to see it in action. Highlights of the system include:
As you can imagine, Thermal Pass can be used for almost any high-traffic location you can think of. But the big question is …. will anybody actually use it? Because truth be told 99% of us are not in a position to be able to assess how any AI solutions of any company stack up against the competition. The only thing we can rely on is AGORACOM’s favourite metric – 3rd party acceptance. In short, if your product is good, people will want it.
By that measure, PAI is off to a great start with:
3rd party acceptance at this early stage – CHECK
Watch our interview with Michael Lende in which we do a deep dive into PAI tech, products and future plans.
AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.
Nowhere is this more important than in the world of disruptive technologies, biotech and pharma. Each of these industries share two distinct traits:
Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.
Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.
Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make. Moreover, he serves as an advisor to several small cap companies.
If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.
Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.
TORONTO, Feb. 11, 2021 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announces that it has completed its previously announced brokered private placement (the “Placement”) of 14,706,000 units of the Company (the “Units”) at a price of $0.85 per Unit (the “Issue Price”) for gross proceeds of approximately $12.5 million. Founder and former chairman of Origin House, Marc Lustig was the lead participant in the Placement.
Cormark Securities Inc. acted as lead agent together with a syndicate of agents that included IBK Capital Corp. and PI Financial Corp. (collectively, the “Agents”). The Agents exercised in full an option (the “Agents’ Option”) for the purchase of an additional 2,941,200 Units on the same terms. Gross proceeds from the exercise of the Agents’ Option were approximately $2.5 million bringing the aggregate proceeds raised from the Placement to approximately $15.0 million from the issuance of the cumulative 17,647,200 Units.
Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional Common Share at a price of $1.15 per Common Share for a period of 24 months from the issuance date thereof. The Warrants are subject to an accelerated expiry, exercisable at the option of the Company, if, on or following the date that is four months and one day after the date of issuance of the Units and prior to the expiry date of the Warrants, the daily volume weighted average trading price of the Common Shares exceeds $2.30 for ten consecutive trading days. The Issue Price represents a discount of 5.5% of the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (“TSXV”) for the 5 trading days ended immediately prior to the announcement of the Placement on January 26, 2021.
Read more: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755177-poet-technologies-completes-c-15-million-private-placement/messages/2303234#message
Los Angeles, CA., Feb. 11, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector. This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.
Every day approximately 10 people around the world lose their lives or are maimed due to an anti-personnel mine (” APM “). This means that about 4,200 people are hurt or killed worldwide every year of which 35-42% are estimated to be children. It is estimated that there are between 60-110 million landmines in the ground right now and an equal amount is in stockpiles waiting to be planted or destroyed. Approximately 82 countries around the world are contaminated by APMs. Source: United Nations, Office for Disarmament Affairs .
An estimated US$540,000,000 was spent by industry and government in 2018 to deal with this problem of Landmines and Explosive Remnants of war (identify multiple APM and improvised explosive devices (IEDs) in a variety of terrain and contexts). Source: Landmine Monitor Report 2019 .
“Since 2020, Draganfly has invested in new capabilities in drone-based magnetometer technology and other remote sensing equipment,” commented Dinesh Kandanchatha, Chairman of Windfall Geotek. “The depth of the Draganfly engineering team, drone services group, and expert advisory in public safety was instrumental to get us to these first tests.”
“Windfall Geotek is the industry leader in AI-based digital exploration for mining. We now have the right mixture of equipment and data to move to the commercialization of an advanced AI-based platform to help solve the global problem of landmines,” said Cameron Chell, CEO of Draganfly. “The two companies share a mission of saving lives through technology. These tests are critical to helping create a new solution to this age-old problem. The new and expanded revenue streams for both companies in the Defense sector, Public Safety, and other markets are significant and represent an area where combined offering can excel.”
“For years our foundation has support organizations removing land mines, this type of technology and innovation by Draganfly and Windfall is exactly what is needed to solve this global challenge on a massive scale,” said Admiral Hayward, former head of the US Navy and member of the Joint Chiefs of Staff.
Watch the video to learn more.
Los Angeles, CA, Feb. 09, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced, subject to customary governance approvals, Jamie P. Dwyer M.D. has joined as a member of the Board of Advisors of Draganfly.
Dr. Dwyer is a professor of medicine at Vanderbilt University, President of the Collaborative Study Group, and Co-Founder of Innovative Renal Care. Previously he served on the faculty of Mayo Clinic.
Dr. Dwyer has extensive experience working with FDA processes in particular devices and software.
Cameron Chell, CEO of Draganfly, said: “We are excited and truly honored to have Dr. Jamie Dwyer join Draganfly’s outstanding Board of Advisors. Dr. Dwyer brings an incredible understanding and experience with FDA processes and will be key in evolving our Vital Intelligence technology.”
“Draganfly has impressed me with the work they have done with their Smart Vital assessment platform and telehealth app. I am honored to assist a company that has built a solid foundation for innovation within the telehealth sector,” said Dr. Jamie Dwyer.
Dr. Dwyer holds an Sc.B degree in mathematics and Latin from Brown University, and an M.D. with Distinction from Brown University Medical School. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at VUMC. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of VUMC in 2008.
Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/754974-dr-jamie-dwyer-professor-of-medicine-at-vanderbilt-university-joins-draganfly-board-of-advisors/messages/2302818#message
New ISO 13485:2016 MDSAP scope paves the way to integration of novel and multiple bio sign monitoring devices for broader patient monitoring solution sales to the consumer and Rx markets globally
Toronto, Ontario–(February 9, 2021) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or the “Company“), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG“) acquisition and management software solutions, has received approval on an expanded ISO 13485:2016 (“ISO“) certification in compliance with the Medical Device Single Audit Program (“MDSAP“) for Canada and the United States, to include pulse oximetry (“PO2“), blood pressure (“BP“), weight and temperature in addition to ECG monitoring hardware and software solutions.
As remote patient monitoring needs continue to grow so does a need for credible data to be collected from people outside of a hospital or medical office. “The expansion of virtual health care is here to stay. Accordingly, many patients are using vital sign/bio sign devices at home for measurements of heart rate, temperature, blood pressure and oxygen saturation. Having easy to use accurate devices is a crucial part of safe virtual care. As an emergency physician I frequently see unnecessary ED visits and “near misses” at home due to inaccurate readings from many popular bio sign devices in current use,” states Dr John Foote, Mount Sinai Hospital Director, Emergency Medicine/Family Medicine Residency Program, Assistant Professor, DFCM, The University of Toronto and a member of the Company’s medical advisory committee.
In addition to providing highly accurate consumer and outpatient ECG monitoring capabilities, the Company has been approached to develop solutions to ensure more traditional measurements are monitored with equal accuracy. To meet these requests, CardioComm’s expanded ISO MDSAP certification scope will allow the Company to develop integrations with one or many devices that can each, or configured as a set of devices, monitor ECGs as well as any other bio signal of interest. Adding PO2, BP and temperature specifically will address 2021 new device integration and product development roadmap plans for the Company including those to be used for COVID-19 related health monitoring.
Since securing its ISO MDSAP certification in 2018, CardioComm has assisted medical device makers to have access for the sale of their medical devices in Canada by placing non-MDSAP ISO-certified devices under the Company’s own MDSAP certification. This has resulted in CardioComm becoming a preferred importer, distributor and reseller of hospital and consumer ECG medical devices for organizations based outside of Canada who do not hold their own ISO certifications under the Canada mandated MDSAP designation. For organizations looking to sell into the US, while ISO under MDSAP is not required for sales into the USA, CardioComm’s Canadian/USA MDSAP certification is accepted by the FDA and removes the need for routine FDA inspections where the registered manufacturer, such as CardioComm, is located in Canada.
The Company will provide additional updates related to multiple bio signal monitoring device integrations and adding new capabilities to its remote patient monitoring technologies.
To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations including those with multiple bio sign monitoring capabilities, please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.
Read More: https://agoracom.com/ir/CardioCommSolutions/forums/discussion/topics/754966-cardiocomm-solutions-expands-iso-clearance-to-include-multiple-biosign-monitoring-device-integrations-in-support-of-remote-patient-monitoring-markets/messages/2302805#message
Topics we discuss:
WHY KWESST? HERE’S SOME GREAT REASONS
1. KWESST is a leader in defensive technologies that increase the capabilities of soldiers, including
those of NATO and its allies.
2. These technologies make a critical difference to soldier safety and effectiveness.
3. The Leadership team experience spans decades and hundreds of millions of dollars in military and homeland security contracts.
4. KWESST develops next-generation systems for forces around the world, with a particular focus on special forces among NATO countries and their allies.
5. KWESST partners with globally recognized equipment manufacturers to integrate its systems into
their solutions to create high value-add products for global customers.
